.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PPCOS II randomized trial compared letrozole with clomiphene for ovulation induction in women with polycystic ovary syndrome and infertility. Letrozole produced a higher cumulative live-birth rate and higher ovulation rate than clomiphene, while multiple pregnancy rates were not significantly higher. The findings established letrozole as a preferred first-line ovulation-induction option for many women with PCOS-related anovulatory infertility. For reproductive-medicine practice, the key is to confirm anovulatory PCOS as the dominant infertility factor before treatment, while assessing tubal and male factors as appropriate. Counseling should address treatment cycles, monitoring, multiple-pregnancy risk and the possibility of moving to gonadotropins or IVF when oral ovulation induction is unsuccessful. The trial also illustrates how a relatively simple modification in first-line therapy can improve reproductive outcomes without requiring escalation directly to advanced ART.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PPCOS II randomized trial compared letrozole with clomiphene for ovulation induction in women with polycystic ovary syndrome and infertility. Letrozole produced a higher cumulative live-birth rate and higher ovulation rate than clomiphene, while multiple pregnancy rates were not significantly higher. The findings established letrozole as a preferred first-line ovulation-induction option for many women with PCOS-related anovulatory infertility. For reproductive-medicine practice, the key is to confirm anovulatory PCOS as the dominant infertility factor before treatment, while assessing tubal and male factors as appropriate. Counseling should address treatment cycles, monitoring, multiple-pregnancy risk and the possibility of moving to gonadotropins or IVF when oral ovulation induction is unsuccessful. The trial also illustrates how a relatively simple modification in first-line therapy can improve reproductive outcomes without requiring escalation directly to advanced ART.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
